Gene therapy for liver cancer- version 1
Research type
Research Study
Full title
Cell-specific expression of a potential RNA gene therapy for Hepatocellular Carcinoma (HCC).
IRAS ID
356139
Contact name
Carin Ingemarsdotter
Contact email
Sponsor organisation
Spliceor Ltd
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
We have developed a novel gene therapy approach for cancer that selectively targets malignant cells while sparing normal tissues, with the goal of improving both efficacy and safety for patients. Our preliminary studies in cell lines have demonstrated proof-of-concept. The next step is to test this strategy in more physiologically relevant models by using primary cancer cells obtained directly from patients alongside primary normal liver cells. In this way, we will assess whether the therapy can discriminate between malignant and healthy cells in a system that better reflects the complexity of cancer. This pilot study is designed to provide the foundation for future clinical translation, with the ultimate aim of advancing toward clinical trials and improved outcomes for patients.
REC name
West Midlands - Coventry & Warwickshire Research Ethics Committee
REC reference
25/WM/0231
Date of REC Opinion
27 Oct 2025
REC opinion
Favourable Opinion